A PHASE I DOSE ESCALATION STUDY EVALUATING THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF CUDC-427, A POTENT, ORAL, MONOVALENT IAP ANTAGONIST, IN PATIENTS WITH REFRACTORY SOLID TUMORS
Tolcher, A., Bendell, J. C., Papadopoulos, K. P., Burris, H. A., Patnaik, A., Fairbrother, W. J., Wong, H., Budha, N., Darbonne, W. C., Peale, F., Mamounas, M., Royer-Joo, S., Yu, R., Portera, C. C.,Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-16-0308
Date:
April, 2016
File:
PDF, 565 KB
english, 2016
File converter
More search results
More benefits 
